An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques

Liqiang Feng, Qian Wang, Chao Shan, Chenchen Yang, Ying Feng, Jia Wu, Xiaolin Liu, Yiwu Zhou, Rendi Jiang, Peiyu Hu, Xinglong Liu, Fan Zhang, Pingchao Li, Xuefeng Niu, Yichu Liu, Xuehua Zheng, Jia Luo, Jing Sun, Yingying Gu, Bo Liu, Yongcun Xu, Chufang Li, Weiqi Pan, Jincun Zhao, Changwen Ke, Xinwen Chen, Tao Xu, Nanshan Zhong, Suhua Guan (), Zhiming Yuan () and Ling Chen ()
Additional contact information
Liqiang Feng: Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Qian Wang: Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Chao Shan: State Key Laboratory of Virology, Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences
Chenchen Yang: Guangzhou nBiomed Ltd
Ying Feng: First Affiliated Hospital of Guangzhou Medical University
Jia Wu: State Key Laboratory of Virology, Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences
Xiaolin Liu: Guangzhou nBiomed Ltd
Yiwu Zhou: Tongji Medical College of Huazhong University of Science and Technology
Rendi Jiang: State Key Laboratory of Virology, Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences
Peiyu Hu: Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Xinglong Liu: Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Fan Zhang: Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Pingchao Li: Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Xuefeng Niu: First Affiliated Hospital of Guangzhou Medical University
Yichu Liu: Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Xuehua Zheng: Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Jia Luo: Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Jing Sun: First Affiliated Hospital of Guangzhou Medical University
Yingying Gu: First Affiliated Hospital of Guangzhou Medical University
Bo Liu: Guangzhou nBiomed Ltd
Yongcun Xu: Guangzhou nBiomed Ltd
Chufang Li: First Affiliated Hospital of Guangzhou Medical University
Weiqi Pan: First Affiliated Hospital of Guangzhou Medical University
Jincun Zhao: First Affiliated Hospital of Guangzhou Medical University
Changwen Ke: Guangdong Provincial Center for Disease Control and Prevention
Xinwen Chen: Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Tao Xu: Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Nanshan Zhong: First Affiliated Hospital of Guangzhou Medical University
Suhua Guan: Guangzhou nBiomed Ltd
Zhiming Yuan: State Key Laboratory of Virology, Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences
Ling Chen: Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences

Nature Communications, 2020, vol. 11, issue 1, 1-11

Abstract: Abstract The rapid spread of coronavirus SARS-CoV-2 greatly threatens global public health but no prophylactic vaccine is available. Here, we report the generation of a replication-incompetent recombinant serotype 5 adenovirus, Ad5-S-nb2, carrying a codon-optimized gene encoding Spike protein (S). In mice and rhesus macaques, intramuscular injection with Ad5-S-nb2 elicits systemic S-specific antibody and cell-mediated immune (CMI) responses. Intranasal inoculation elicits both systemic and pulmonary antibody responses but weaker CMI response. At 30 days after a single vaccination with Ad5-S-nb2 either intramuscularly or intranasally, macaques are protected against SARS-CoV-2 challenge. A subsequent challenge reveals that macaques vaccinated with a 10-fold lower vaccine dosage (1 × 1010 viral particles) are also protected, demonstrating the effectiveness of Ad5-S-nb2 and the possibility of offering more vaccine dosages within a shorter timeframe. Thus, Ad5-S-nb2 is a promising candidate vaccine and warrants further clinical evaluation.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-020-18077-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18077-5

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-18077-5

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().